BRVEBraveheart Bio
临床阶段生物制药公司，专注开发心肌病口服小分子抑制剂疗法
$18发行价
$383M融资额
$29.8首日收盘
12.22%首日表现
临床阶段生物制药公司，专注开发心肌病口服小分子抑制剂疗法
公司简介（来源：StockAnalysis）
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
51CFO 判断：需精通临床管线财务建模、FDA路径资金规划及生物制药资本效率管理的CFO
管理层与创始团队详情以 SEC 招股书披露为准
你的公司需要这样的 CFO 吗？
51CFO 是专注美股市场的投行团队：赴美 IPO、借壳上市、壳公司买卖、SPAC 与 De-SPAC、SEC 申报与上市后再融资，从架构到敲钟一条龙操盘。免费 30 分钟上市路径诊断，24 小时内回复。
预约咨询